Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26016463 | 0.83 | HRH3 (0.34) | — | |
| SCHEMBL20128874 | 0.83 | HRH3 (0.34) | — | |
| SCHEMBL16940018 | 0.83 | HRH3 (0.34) | — | |
| SCHEMBL26016349 | 0.83 | HRH3 (0.34) | — | |
| SCHEMBL25890689 | 0.83 | HRH3 (0.34) | — | |
| SCHEMBL18590263 | 0.83 | — | — | |
| SCHEMBL17886014 | 0.83 | HRH3 (0.34) | — | |
| SCHEMBL12247055 | 0.83 | HRH3 (0.34) | — | |
| SCHEMBL12247023 | 0.83 | HRH3 (0.34) | — | |
| SCHEMBL10038935 | 0.81 | HRH3 (0.32) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | SEAGEN INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| US-20240216526-A1 | PREPARATION METHOD FOR DUAL-DRUG-LINKER OF ADC AND USE THEREOF | CHENGDU SCIMOUNT PHARMATECH CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216420-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | SEAGEN INC (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240218523-A1 | CORROSION RESISTANT COATING SYSTEMS | THE BOEING COMPANY | 2024-07-04 | — | — | US | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20240016940-A1 | LONG-ACTING AND LONG-CIRCULATING DELIVERY VEHICLES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-01-18 | — | — | US | disclosed |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080146475-A1 | Polyalkyl (Meth) Acrylate Copolymers Having Outstanding Properties | ROHMAX ADDITIVES GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| US-7378518-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070232735-A1 | Organic silicon compound, hydophilic composition containing the same and hydrophilic member | FUJIFILM CORPORATION (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070155676-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2007-02-22 | — | — | US | disclosed |
| EP-1655291-A1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. (JP) | 2006-05-10 | — | — | EP | disclosed |
| EP-0284005-B1 | METHOD OF PRODUCTION OF POLYOLEFINS | IDEMITSU PETROCHEMICAL CO. LTD. (JP) | 1991-12-18 | — | — | EP | disclosed |
| US-4981930-A | POLYMERIZATION CATALYSTS | IDEMITSU PETROCHEMICAL COMPANY LIMITED (JP) | 1991-01-01 | — | — | US | disclosed |
| EP-0284005-A2 | Method of production of polyolefins | IDEMITSU PETROCHEMICAL CO. LTD. (JP) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | MAPK1 772/4885ALDH1A1 2211/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | MAPK1 2099/4885ALDH1A1 3778/4885 |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | MAPK1 3405/4885ALDH1A1 1971/4885 |
| US-20240016940-A1 | LONG-ACTING AND LONG-CIRCULATING DELIVERY VEHICLES | VEGFA, LDLR, LIPG | MAPK1 4187/4885ALDH1A1 3911/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | MAPK1 4831/4885ALDH1A1 2867/4885 |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | DHFR, NAT1, ACR | MAPK1 2111/4885ALDH1A1 10/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | MAPK1 1305/4885ALDH1A1 148/4885 |
| US-20070232735-A1 | Organic silicon compound, hydophilic composition containing the same and hydrophilic member | H1-3, H1-0, H1-2 | MAPK1 4014/4885ALDH1A1 3920/4885 |
| US-20240216420-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | MSN, AURKA, AURKC | MAPK1 3153/4885ALDH1A1 2389/4885 |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | CTSB, CTSE, CTSZ | MAPK1 4759/4885ALDH1A1 3445/4885 |
| US-20240216526-A1 | PREPARATION METHOD FOR DUAL-DRUG-LINKER OF ADC AND USE THEREOF | SKP1, ADCY7, ERBB2 | MAPK1 822/4885ALDH1A1 1714/4885 |
| US-20070155676-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | APOB, NPC1L1, CYP46A1 | MAPK1 3541/4885ALDH1A1 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.